IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026 at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference Wednesday, March 11, 2026 at 10:00 a.m. ET at the Leerink Global Healthcare Conference A live webcast of each presentation will be available on the Edwards investor relations website at http://ir.edwards.com/, wit.

U.S. medical device maker Edwards Lifesciences has scrapped its anti-copycat policy that triggered a complaint from an Indian rival, EU antitrust regulators said on Monday as they closed their investigation into the company.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards L.

Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-seven analysts that are covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the

More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

With Edwards Lifesciences getting a key earnings report out of the way, the uncertainties hanging over EW stock has cleared for the bulls.

Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.

Total Sales: $1.57 billion, grew 11.6% year over year.Adjusted EPS: $0.58, lower due to higher spending and tax rate.GAAP EPS: $0.11, impacted by one-time char

Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript